Basic Information
| LncRNA/CircRNA Name | BDLNR |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Baicalein | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot, RIP |
| Sample | cervical cancer tissues, cell lines (HeLa, SiHa, ME-180, and Caski,H8) |
| Expression Pattern | up-regulated |
| Function Description | BDLNR physically bound to YBX1, recruited YBX1 to PIK3CA promoter, activated PIK3CA expression and PI3K/Akt pathway.BDLNR was upregulated in cervical cancer and associated with poor prognosis of cervical cancer patients. BDLNR mediated the anti-cancer effects of baicalein in cervical cancer via activating PI3K/Akt pathway and BDLNR would be potential therapeutic target for enhancing the anti-cancer effects of baicalein in cervical cancer.upregulated BDLNR expression indicated poor overall survival of cervical cancer patients. |
| Pubmed ID | 29175387 |
| Year | 2017 |
| Title | Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway. |
External Links
| Links for BDLNR | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |